Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bernhard

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
NPJ Genomic Medicine|September 6, 2022
Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1Sergey V Lobanov, Branduff McAllister, Mia McDade-Kumar, et al.
Human Brain Mapping|August 2, 2016
Natural variation in sensory-motor white matter organization influences manifestations of Huntington's diseaseMichael Orth, Sarah Gregory, Rachael I Scahill, et al.
Journal of Neurology|July 25, 2025
Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseasesSteffen Halbgebauer, Veronika Klose, Badrieh Fazeli, et al.
Ebiomedicine|December 3, 2015
Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD StudyStefan Klöppel, Sarah Gregory, Elisa Scheller, et al.
Scientific Reports|January 3, 2025
Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseasesSára Mravinacová, Sofia Bergström, Jennie Olofsson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansionPeggy Barschke, Patrick Oeckl, Petra Steinacker, et al.
The New England Journal of Medicine|May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's DiseaseSarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
American Journal of Human Genetics|March 24, 2022
Genetic modifiers of Huntington disease differentially influence motor and cognitive domainsJong-Min Lee, Yuan Huang, Michael Orth, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 17, 2017
Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progressionPetra Steinacker, Federico Verde, Lubin Fang, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
NPJ Genomic Medicine|September 6, 2022
Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1Sergey V Lobanov, Branduff McAllister, Mia McDade-Kumar, et al.
Human Brain Mapping|August 2, 2016
Natural variation in sensory-motor white matter organization influences manifestations of Huntington's diseaseMichael Orth, Sarah Gregory, Rachael I Scahill, et al.
Journal of Neurology|July 25, 2025
Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseasesSteffen Halbgebauer, Veronika Klose, Badrieh Fazeli, et al.
Ebiomedicine|December 3, 2015
Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD StudyStefan Klöppel, Sarah Gregory, Elisa Scheller, et al.
Scientific Reports|January 3, 2025
Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseasesSára Mravinacová, Sofia Bergström, Jennie Olofsson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansionPeggy Barschke, Patrick Oeckl, Petra Steinacker, et al.
The New England Journal of Medicine|May 7, 2019
Targeting Huntingtin Expression in Patients with Huntington's DiseaseSarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, et al.
British Journal of Clinical Pharmacology|September 17, 2014
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's diseaseSigurd D Süssmuth, Salman Haider, G Bernhard Landwehrmeyer, et al.
American Journal of Human Genetics|March 24, 2022
Genetic modifiers of Huntington disease differentially influence motor and cognitive domainsJong-Min Lee, Yuan Huang, Michael Orth, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 17, 2017
Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progressionPetra Steinacker, Federico Verde, Lubin Fang, et al.
Pageof 16